

Summary of Products Characteristics

1. Name of the medicinal Product

Paracetamol Injection 150 mg/ml

2. Qualitative and Quantitative Composition

Paracetamol BP

This product contains Paracetamol 150 mg/ml solution for injection

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

IM/IV

A clear colourless solution.

4. Clinical Particulars

1. Therapeutic Indications

Paracetamol 150 mg/ml solution for injection is indicated for the mild to moderate pain, pyrexia (pyrexia with discomfort in children).

4.2 Posology and Method of Administration

Paracetamol 150 mg/ml solution for injection based in 10 mg/kg body weight, to be given via slow IV push or via deep IM injection, every 4-6 hours a day, or approximately as follows:

Age Group	IV/IM dose every 4 to 6 hours
Children	
<6 months	0.25-0.5 mL
6-12 months	0.5-0.75 mL
1-2 years	0.75-1 mL
3-6 years	1-1.25 mL
7-12 years	1.25-2 mL
Adults	2-4 mL

Method of administration: Paracetamol 150 mg/ml solution for injection may be given 4-6 hours via slow IV push or via deep IM injection while symptoms persist, but not to exceed 5 doses in each 24-hr period for not >5 days unless otherwise directed by a physician.

3. Contraindications

It is contraindicated in patients with known hypersensitivity to Paracetamol to any of the excipients of the formulation. In cases of severe hepatocellular insufficiency.

4. Special Warnings and Special Precautions for Use

Hepatic injury: Administration of Paracetamol in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. Do not exceed the maximum recommended daily dose of paracetamol.

Use caution when administering paracetamol in patients with hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia (e.g., due to dehydration or blood loss), or severe renal impairment (creatinine clearance \leq 30 mL/min).

Patients should take precaution if your baby is less than 4 weeks old, consult and take advice to your physician or pharmacist before giving them paracetamol 150 mg/ml solution for injection in particular if the baby is given other medicines that contain propylene glycol or alcohol.

Pregnancy: There are no studies of intravenous paracetamol in pregnant women; however, epidemiological data on oral Paracetamol use in pregnant women show no increased risk of major congenital malformations. Paracetamol injection should be given to a pregnant woman only if clearly needed.

Lactation: Paracetamol is excreted in breast milk in small quantities. No undesirable effects on nursing infants have been reported. Paracetamol injection may be used in breast-feeding women.

5. Interaction with other medicinal products and other forms of interaction

Anticoagulants: Prolonged regular use of paracetamol possibly enhances anticoagulant effect of coumarins.

Antidiabetics: Absorption of paracetamol possibly reduced when given 1 to 4 hours after lixisenatide.

Antiepileptics: Metabolism of paracetamol possibly accelerated by carbamazepine, phenobarbital and phenytoin (also isolated reports of hepatotoxicity).

Cytotoxics: Paracetamol possibly inhibits metabolism of intravenous busulfan (manufacturer of intravenous busulfan advises caution within 72 hours of paracetamol); caution with paracetamol advised by manufacturer of imatinib.

Lipid-regulating Drugs: Absorption of Paracetamol reduced by colestyramine.

Metoclopramide: Rate of absorption of Paracetamol increased by metoclopramide.

6. Pregnancy and Lactation

Pregnancy: There are no studies of intravenous paracetamol in pregnant women; however, epidemiological data on oral Paracetamol use in pregnant women show no increased risk of major congenital malformations. Paracetamol injection should be given to a pregnant woman only if clearly needed.

Lactation: Paracetamol is excreted in breast milk in small quantities. No undesirable effects on nursing infants have been reported. Paracetamol injection may be used in breast-feeding women.

7. Effects on ability To Drive and use Machines

Not relevant

8. Undesirable effect

Side-effects rare, malaise, skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis; blood disorders including thrombocytopenia, leucopenia, neutropenia reported; hypotension, flushing, and tachycardia reported on infusion.

9. Overdose

Symptoms: Acute overdose with Paracetamol may also lead to acute renal tubular necrosis. Symptoms generally appear within the first 24 hours and comprise of nausea, vomiting, anorexia, pallor and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis may occur.

Treatment: Treatment of paracetamol overdose may include the antidote N-acetyl cysteine (NAC) by the IV or oral route. In overdoses of oral paracetamol NAC is administered, if possible, before 10 hours but may give some degree of protection from liver toxicity even after this time. Other symptomatic and supportive treatment.

5. Pharmacological Properties

5.1. Pharmacodynamics Properties

Paracetamol may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and, to a lesser extent, through a peripheral action by blocking pain impulse generation. The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation. Paracetamol probably produces antipyresis by acting centrally on the hypothalamic heat regulating centre to produce peripheral vasodilation resulting in increased blood flow through the skin, sweating and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus.

5.2. Pharmacokinetic Properties

Absorption: Paracetamol pharmacokinetics is linear up to 2 g after single administration and after repeated administration during 24 hours.

Distribution: The volume of distribution of Paracetamol is approximately 1 L/kg. Paracetamol is not extensively bound to plasma proteins.

Metabolism: Paracetamol Injection is metabolized mainly in the liver following two major hepatic pathways: glucuronic acid conjugation and sulphuric acid conjugation. The later route is rapidly saturable at doses that exceed the therapeutic doses. A small fraction (less than 4%) is metabolised by cytochrome P450 to a reactive intermediate (N-acetyl benzoquinone imine) which, under normal conditions of use, is rapidly detoxified by reduced glutathione and eliminated in the urine after conjugation with cysteine and mercapturic acid.

Half-life: Plasma elimination half-life is approximately 2.7 hours.

Excretion: The metabolites of paracetamol are mainly excreted in the urine. 90% of the dose administered is excreted within 24 hours, mainly as glucuronide (60-80%) and sulphate (20-30%) conjugates. Less than 5% is eliminated unchanged.

5.3. Preclinical Safety Data

Preclinical data reveal no special hazard for humans beyond the information included in other sections of the SmPC.

Studies on local tolerance of Paracetamol Solution for Infusion in rats and rabbits showed good tolerability. Absence of delayed contact hypersensitivity has been tested in guinea pigs.

6. Pharmaceutical Particulars

6.1. List of Excipients

Propylene Glycol
Benzyl Alcohol
Macrogol (Polyethylene Glycol 400)
Sodium Metabisulphite
Sodium Acetate Anhydrous
Glacial Acetic Acid
Water for Injection

6.2 Incompatibilities

Not applicable

6.3 Shelf Life

24. months

6.4 Special Precautions for Storage

Store below 30°C. Protect from light.

5. Nature and Contents of Container

Clear colourless solution filled in 2 ml amber colour white autocut ring ampoule. Such 10 labeled ampoules are blister packed with LPL logo printed paper foil. Such 1 blister is packed in a printed carton with packing insert.

6. Special precaution for disposal and other handling

Waste must be disposed of in accordance with federal, state and local environmental control regulations.

7. Marketing Authorization Holder And Manufacturing Site Addresses

Name and Address of Marketing Authorization Holder

Lincoln Pharmaceuticals Limited

Trimul Estate, Khatraj, Taluka: Kalol,
District: Gandhinagar Gujarat, India.
Telephone no.: +91-79-41078096
Fax: +91-79-41078062
E-mail: hiren@lincolnpharma.com
Website: www.lincolnpharma.com

Name and Address of manufacturing site(s)

Lincoln Parenterals Limited

11, Trimul Estate, Khatraj, Taluka: Kalol,
District: Gandhinagar Gujarat, India.
Telephone no.: +91-79-41078096
Fax: +91-02764-281809
E-mail: hiren@lincolnpharma.com
Website: www.lincolnpharma.com

8. Marketing Authorization Number

TAN 22 HM 0013

9. Date of First <Registration> / Renewal of The <Registration>

10/01/2022

10.0 Date of Revision of the Text